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ABSTRACT
Objectives To compare the use of benzodiazepines, z- 
hypnotics, gabapentinoids, opioids and centrally acting 
stimulants (CAS) among patients who had received opioid 
agonist therapy (OAT) in Norway and Sweden during the 
period 2015 - 2017.
Design A register- based prospective cohort study using 
information about dispensed drugs from the Norwegian 
Prescription Database and Swedish Prescribed Drug 
Register.
Setting Patients who were dispensed OAT opioids from 
pharmacies.
Participants A total of 7176 Norwegian and 3591 
Swedish patients on OAT were included.
Outcome measures The number and frequency of 
potentially addictive drugs dispensed were calculated for 
the two countries. The mean daily doses of dispensed 
benzodiazepines and z- hypnotics were summarised by 
calculating benzodiazepines in diazepam equivalents and 
z- hypnotics in zopiclone equivalents.
Results In 2017, 46% of patients in Norway, and 15% 
in Sweden, were dispensed a benzodiazepine. Moreover, 
14% in Norway and 26% in Sweden received z- hypnotics. 
Gabapentinoids were dispensed to 10% of patients in 
Norway and 19% of patients in Sweden. In Norway, 6% 
and 12% of the patients received strong and weak non- 
OAT opioids, respectively, whereas in Sweden 10% were 
dispensed strong non- OAT opioids and 5% weak non- OAT 
opioids . CAS were dispensed to 4% in Norway and 18% 
in Sweden. The mean daily doses of benzodiazepines 
were 16 and 17 mg diazepam equivalents in Norway and 
Sweden, respectively. For z- hypnotics, the mean daily 
dose was 8 mg zopiclone equivalents in both countries. 
‘Benzodiazepines and z- hypnotics’ was the most 
dispensed drug combination in 2017. Similar results were 
found in 2015 and 2016.
Conclusions Nearly half of those patients who were 
dispensed an OAT opioid in Norway and Sweden were 
dispensed potentially addictive drugs. The differences 
identified between Norway and Sweden might be related 
to differences in eligibility guidelines and restrictions with 
respect to OAT.
INTRODUCTION
Several studies indicate that around 50% of 
those patients who receive opioid agonist 
therapy (OAT) are dispensed benzodiaz-
epines (e.g., diazepam and oxazepam), 
z- hypnotics (zolpidem and zopiclone), 
gabapentinoids (pregabalin and gabapentin), 
non- OAT opioids (e.g., morphine and 
oxycodone) or centrally acting stimulants 
(CAS) (e.g., methylphenidate and lisdexa-
mphetamine) yearly1–5, notwithstanding 
the use of any potentially addictive illicit 
drugs.1 6 7 Prescribing potentially addictive 
drugs to patients on OAT is controversial and 
comes with pros and cons.1 8 Combinations 
of several potentially addictive drugs may 
increase the risk of non- fatal or fatal over-
doses,1 as well as amplify negative complex 
medical and psychosocial challenges such 
as unemployment,9 criminal behaviour10 
and discontinuation of OAT.6 11–13 However, 
the majority of patients on OAT have psychi-
atric and physical comorbidities, including 
psychotic disorders, attention deficit 
Strengths and limitations of this study
 ► This study used national register- based data of 
drugs dispensed from pharmacies in Norway and 
Sweden.
 ► This study did not capture patients who were dis-
pensed opioid agonist therapy (OAT) opioids from 
entities other than pharmacies.
 ► There is potential for misclassification of patients if 
dispensed opioids were dispensed on medical indi-
cations other than OAT.
 ► About 40% and 10% of OAT patients in Sweden and 
Norway, respectively, were not identified by using 
these national register- based data.
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hyperactivity disorder (ADHD), personality disorders, 
depression, other substance use disorders besides opioid 
addiction or injection- related diseases such as hepatitis 
C virus infection.14–16 The wide range of high- prevalent 
comorbidities can require coprescriptions of potentially 
addictive drugs to obtain an optimal medical treatment 
in the OAT population. Examples such as prescriptions 
of CAS in order to improve ADHD symptoms17 and short- 
term prescriptions of benzodiazepines to treat psycho-
motor agitation caused by stimulant intoxications18 or 
seizure prophylaxis, as in cases of benzodiazepine or 
alcohol withdrawal,19 illustrate clinical indications for 
such coprescriptions.
The prevalence of potentially addictive drugs 
dispensed among patients on OAT varies between coun-
tries.1 5 20–23 In the USA, in 2013, between 22% and 
65% of patients on OAT were dispensed benzodiaze-
pines, and 42% and 20% were dispensed benzodiaze-
pines and z- hypnotics, respectively, in the UK between 
1998 and 2014.20 24 In Sweden, 41% of OAT patients 
were dispensed z- hypnotics in the period 2005–2012.1 
Furthermore, epidemiological studies have shown that 
a wide range of OAT patients, from 8% to 22%, were 
dispensed gabapentinoids in different countries,1 3 24 
while between 12% and 34% were dispensed non- OAT 
opioids.21 22 25 In contrast, no studies have evaluated CAS 
dispensing among patients on OAT. Overall, there are 
substantial intercountry differences regarding patients 
on OAT who were dispensed potentially addictive 
drugs; however, there is a gap in knowledge concerning 
whether these differences still persist.
OAT has in recent decades been increasingly applied 
as an effective and well- documented treatment for opioid 
addiction.26–29 In Norway, around 7500 patients currently 
receive OAT,28 while the corresponding number for 
Sweden is nearly 4400 patients.30 Research on differences 
and similarities in the dispensing practice of potentially 
addictive drugs in these countries needs to be investigated 
to optimise the use of these drugs in the OAT population. 
In addition, evaluating dispensed doses of benzodiaze-
pines, z- hypnotics, pregabalin, gabapentin and the CASs 
methylphenidate and lisdexamphetamine - the first hand 
of choice in the treatment of ADHD - are of particular 
interest due to the risk of overdoses and intoxications. It 
is also important for the study of possible variations in 
dispensed doses between the two countries.
Thus, this study aims to describe the rates and doses 
of potentially addictive drugs dispensed from Norwegian 
and Swedish pharmacies to patients receiving OAT in the 
period 2015–2017. We aim to describe the following:
1. The dispensing rates of benzodiazepines, z- hypnotics, 
gabapentinoids, non- OAT opioids and CAS per calen-
dar year.
2. The mean daily doses of dispensed benzodiazepines, 
z- hypnotics, pregabalin, gabapentin, lisdexamphet-
amine and methylphenidate per calendar year.
3. The most commonly dispensed combinations of po-
tentially addictive drug groups: benzodiazepines, 
z- hypnotics, gabapentinoids, non- OAT opioids and/or 
CAS among patients on OAT in 2017.
METHODS
Data sources
Data were retrieved from the Norwegian Prescription 
Database and Swedish Prescribed Drug Register. From 1 
January 2004 in Norway and 1 July 2005 in Sweden, all 
pharmacies are obliged to submit electronically all data 
regarding dispensed drugs to the Norwegian Prescrip-
tion Database and Swedish Prescribed Drug Register. 
The Norwegian Prescription Database and Swedish 
Prescribed Drug Register are administered and regu-
lated by the Norwegian Institute of Public Health and 
Swedish National Board of Health and Welfare, respec-
tively. Both registers contain information on all drugs 
dispensed from pharmacies, with unique patient identi-
fiers, except for drugs administered at hospitals, nursing 
homes and outpatient clinics.31 32 The Anatomical Ther-
apeutic Chemical (ATC) classification system was used in 
accordance with the WHO standards per 2018.33 A recent 
report evaluating OAT stated that the Swedish Prescribed 
Drug Register identifies about 60% of patients on OAT,27 
while the Norwegian Prescription Database is assumed to 
identify about 90% of the patients.28 Moreover, in 2016, 
Sweden changed the OAT eligibility criteria by including 
long- term use of opioids (not only opiates like heroin, 
opium and morphine) as analgesics for chronic, severe 
pain.26 27 Inclusion criteria in this study, therefore, identi-
fied patients with a high opiate tolerance who had a high 
degree of continuity in their OAT treatment.
Study population
All patients between 18 and 75 years of age who received 
at least one mean defined daily dose (DDD) of one or 
more defined OAT opioids per day during 2015, 2016 or 
2017 were included (see online supplementary table S1). 
A minimum of one mean DDD per day was set as a crite-
rion for inclusion to exclude patients who were dispensed 
low- dosed OAT opioids on medical indications other 
than OAT. The DDD of OAT opioids was calculated for 
each calendar year separately, which means that patients 
were only included in the calendar year when the mean 
dispensed DDD per day of OAT opioids, measured in 
DDD divided by 365.25 days, was one or more. The type 
of OAT opioids that were the latest dispensed (calculated 
in DDD) per year determined which type of OAT opioid 
category the patients belonged to in a calendar year. 
Dispensing methadone tablets or injections as well as 
buprenorphine formulations (ATC code: N02AE01) that 
have other medical indications besides OAT in Norway 
and Sweden, were excluded in the calculation of mean 
DDD of OAT opioids per day.
Patient and public involvement
Patients and the public were not involved in the devel-
opment of the study design, planning and recruitment. 
Study results were not distributed to the patients after 
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the study. All data were handled strictly confidentially 
and anonymously. The Strengthening the Reporting 
of Observational Studies in Epidemiology Guidance 
checklist was applied during the preparation of the 
study.
Definitions of OAT opioids, other potentially addictive drugs 
and drug groups
All the potentially addictive drugs in the drug groups 
of benzodiazepines, z- hypnotics, gabapentinoids, OAT 
opioids, non- OAT opioids and CAS, which had marketing 
authorisations in Norway or Sweden in the period from 
2015 to 2017, were included. All included drugs were 
defined according to their ATC codes. In addition, the 
non- OAT opioids were divided into two groups: ‘strong 
non- OAT opioids’ and ‘weak non- OAT opioids’ according 
to their analgesic potency.
Analysis strategy and statistical analyses
Data analysis
The age of included patients per year was calculated by 
subtracting the dispensing year from the birth year. The 
age of patients was categorised into four groups: 18–35, 
36–45, 46–55 and 56–75.
The dispensing rates per year were defined as all 
included patients who were dispensed at least one poten-
tially addictive drug during a calendar year divided by the 
number of included patients in the same year. The rates 
were calculated for each drug and the respective drug 
groups.
The mean daily doses per year of all dispensed benzo-
diazepines, z- hypnotics, pregabalin, gabapentin, lisdexa-
mphetamine and methylphenidate were calculated by 
summing all dispensed DDD of each potentially addictive 
drug per calendar year in the study period. The DDD 
of each drug was converted to milligrams by using the 
definitions of the WHO Collaboration Centre for Drug 
Statistics Methodology (see online supplementary table 
S2).33 The dispensed doses (in milligrams) of each drug 
were divided by 365.25 days to calculate the mean daily 
doses per year. Further, the mean daily dose per year of 
each dispensed benzodiazepine was converted to mean 
daily dispensed diazepam equivalents according to the 
equivalency table stated by the Norwegian Directorate 
of Health and a study evaluating the equipotency of 
lorazepam versus diazepam (see online supplementary 
figure S1).34 35 The dispensed diazepam equivalents per 
day were used to calculate the total sum of all dispensed 
benzodiazepines per day per year. The mean daily doses 
of dispensed z- hypnotics were calculated by converting 
mean dispensed zolpidem dose per day to zopiclone 
equivalents according to the guidelines of the Norwegian 
Directorate of Health.34 Furthermore, the total mean 
doses per day of zopiclone and zolpidem in zopiclone 
equivalents for a calendar year were summed.
Statistical analyses
Means, medians, percentiles and percentages were used 
to calculate dispensing rates, and the dispensed doses of 
benzodiazepines, z- hypnotics, pregabalin, gabapentin, 
lisdexamphetamine and methylphenidate. Stata SE V.16.0 
statistical software was used for all analyses.
RESULTS
Descriptive characteristics
A total of 7176 Norwegian and 3591 Swedish patients on 
OAT were included in the study period (table 1). In 2015, 
6007 patients in Norway, and 2640 in Sweden fulfilled 
the inclusion criteria (see online supplementary figure 
S2). A further 5542 OAT patients in Norway, and 2683 
OAT patients in Sweden were included in 2016, with 5556 
Norwegian OAT patients and 2739 Swedish OAT patients 
having fulfilled the eligibility criteria in 2017.
In 2017, 72% and 70% of the Norwegian and Swedish 
patients were male, respectively. The mean age of the 
patients included was 46 years in Norway and 45 years in 
Sweden. Buprenorphine/buprenorphine- naloxone was 
the most dispensed OAT opioid throughout the study 
period, having been dispensed to 55% of patients in 
Norway and 57% of patients in Sweden. The findings in 
2015 and 2016 were similar.
Dispensing rates of potentially addictive drugs
In Norway, 56% of patients on OAT were dispensed 
benzodiazepines, z- hypnotics, gabapentinoids, non- OAT 
opioids or CAS in 2015 (table 2). In 2017, the propor-
tion was 59%. In Sweden, the proportion of patients on 
OAT who received at least one dispensation of these 
potentially addictive drugs was 56% in 2015 and 55% 
in 2017 (figure 1). In 2017, the proportion of patients 
receiving benzodiazepines was 46% in Norway and 15% 
in Sweden. Furthermore, 14% in Norway and 26% in 
Sweden received z- hypnotics, and 10% of the Norwegian 
patients and 19% of the Swedish patients were dispensed 
gabapentinoids. CAS were dispensed to 4% of the Norwe-
gian patients and 18% of the Swedish patients on OAT. 
Similar results were also achieved in 2015 and 2016 (see 
online supplementary figure S3).
Dispensed doses of benzodiazepines, z-hypnotics, gabapentin, 
pregabalin, lisdexamphetamine, and methylphenidate
In 2017, the mean doses of dispensed benzodiazepines 
were 17 mg/day diazepam equivalents in Norway, with a 
corresponding 16 mg/day in Sweden (table 3). Further, 
the mean dose of dispensed z- hypnotics was 8 mg/day 
zopiclone equivalents in both countries in 2017. The 
mean daily doses of dispensed pregabalin, gabapentin 
and lisdexamphetamine were higher in Norway than 
in Sweden (pregabalin: 402 mg vs 345 mg, gabapentin: 
1021 mg vs 772 mg and lisdexamphetamine: 58 mg vs 
51 mg), while the mean dose of dispensed methylphe-
nidate per day was higher in Sweden compared with 
Norway (methylphenidate: 80 mg vs 57 mg). The results 
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were relatively similar in 2015 and 2016 except for the 
mean dose of dispensed lisdexamphetamine per day, 
which was higher (in mg) in Sweden than in Norway in 
2015 (lisdexamphetamine: 42 mg vs 13 mg).
Combinations of potentially addictive drugs in 2017
The proportion of patients on OAT being dispensed 
a single potentially addictive drug was 34% in Norway 
and 31% in Sweden. A quarter were dispensed poten-
tially addictive drugs from two or more drug groups (see 
online supplementary table S3). ‘Benzodiazepines and 
z- hypnotics’ was the most commonly dispensed combi-
nation of drugs, whereas ‘benzodiazepines and non- 
OAT opioids’ and ‘z- hypnotics and gabapentinoids’ were 
the second most common combinations in Norway and 
Sweden, respectively.
DISCUSSION
The proportion of patients on OAT who were dispensed 
a potentially addictive drug was unchanged during the 
study period, with about half of the patients in both coun-
tries. There were, however, substantial variations between 
the countries in all dispensed drug groups. Benzodiaze-
pines and weak non- OAT opioids were more commonly 
dispensed in Norway than in Sweden. In contrast, z- hyp-
notics, gabapentinoids, CAS and strong non- OAT opioids 
were more frequently dispensed in Sweden compared 
with Norway. Similar variations between Norway and 
Sweden have also been found regarding dispensing weak 
and strong non- OAT opioids in the general population.36 
The most frequent combinations of potentially addic-
tive drugs with OAT medications in 2017 were observed 
for benzodiazepines and z- hypnotics in both countries. 
The mean daily doses of dispensed benzodiazepines and 
z- hypnotics were also similar between the countries, while 
pregabalin, gabapentin and lisdexamphetamine doses 
were higher (in mg) in Norway. The mean daily dose of 
methylphenidate was higher (in mg) in Sweden compared 
with Norway. Similar results were found in 2015 and 2016.
The Swedish OAT guidelines recommend restrained 
practice in dispensing potentially addictive drugs,26 27 
while Norway goes further by downright discouraging 
benzodiazepine use in OAT. It was, therefore, particularly 
surprising that only 15% of the patients in Sweden were 
dispensed benzodiazepines, whereas, in Norway, benzo-
diazepines were dispensed to about half of the OAT 
patients. However, the dispensing rates of z- hypnotics and 
gabapentinoids were higher in Sweden than in Norway. 
The fact that the prevalence of mental and physical disor-
ders is high among patients on OAT - and that there is 
a broad spectrum of medical indications for the use of 
benzodiazepines, gabapentinoids and z- hypnotics - makes 
it challenging to determine whether our results point 
towards inappropriate dispensing practice in the OAT 
populations in each country.14 15 37–39 It is nevertheless 
noteworthy that the dispensing rates of these drugs devi-
ated considerably between the two countries.
Sweden had dispensing rates nearly four times higher 
for CAS compared with Norway, which indicates that 
coverage of ADHD treatment in patients on OAT is higher 
in Sweden. In both countries, guidelines for ADHD treat-
ment recommend abstinence from other potentially 
addictive drugs when CAS are dispensed to patients on 
OAT.40 In addition, the Norwegian guidelines recommend 
Table 1 Basic characteristics of patients receiving opioid agonist therapy in Norway and Sweden
Baseline characteristics
2015 2016 2017
Norway Sweden Norway Sweden Norway Sweden
No. % No. % No. % No. % No. % No. %
Patients 6007 2640 5542 2683 5556 2739
  Age
  ≥18–35 1132 19 648 25 958 17 649 24 881 16 647 24
  >35–45 2043 34 786 30 1815 33 806 30 1751 32 819 30
  >45–55 2096 35 737 28 1961 35 708 26 2000 36 713 26
  >55–≤75 736 12 469 18 808 15 520 19 924 17 560 20
  Mean (SD) 45 (9) 44 (11) 45 (9) 45 (11) 46 (9) 45 (11)
Gender
  Male 4225 70 1886 71 3897 70 1939 72 3878 70 1961 72
  Female 1782 30 754 29 1645 30 744 28 1678 30 778 28
OAT opioids*
  Methadone/levomethadone 2747 46 1229 47 2389 43 1209 45 2533 46 1191 43
  Buprenorphine/buprenorphine- naloxone 3260 54 1411 53 3153 57 1474 55 3023 54 1548 57
*Patients were categorised in the groups ‘Methadone/Levomethadone’ and ‘Buprenorphine/buprenorphine- naloxone’. The type of OAT 
opioids was calculated based on the most dispensed OAT opioid measured in DDD per calendar year.
DDD, defined daily dose; No., number of patients; OAT, opioid agonist therapy.
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documented abstinence from potentially addictive drugs 
at least 3 months prior to the initiation of CAS in OAT 
patients when indicated.41 This may partly explain a lower 
dispensing rate of CAS in Norway compared with Swedish 
OAT patients. Furthermore, unlike Norway, Sweden 
seems to terminate OAT in cases of repeated illicit drug 
use, which indicates that the coverage of OAT among 
patients with severe opioid addiction may be lower in 
Sweden.30 42 This can explain why the proportion of OAT 
patients who meet the criteria for codispensing CAS is 
higher in Sweden compared with Norway.
The differences in dispensing rates and mean daily 
doses of codispensed potentially addictive drugs between 
Norway and Sweden may also be explained by the compo-
sition and heterogeneity of OAT populations. The Euro-
pean Monitoring Centre for Drugs and Drug Addiction, 
evaluating OAT in 12 European countries,29 points out 
that restrictive policy, narrow inclusion criteria and costs 
are seen as substantial challenges limiting the coverage of 
OAT. In general, patients who repeatedly use illicit drugs 
in OAT have more psychiatric and somatic comorbidi-
ties.43–45 In Sweden, repeated use of illicit drugs in OAT 
may cause patients to be terminated from OAT against 
their will.42 This is to believe that Norway probably has 
a higher coverage of OAT, which also includes patients 
using illegal drugs and, accordingly, those with a higher 
burden of comorbid diseases. In addition, the divergent 
dispensing practices in the two countries could reflect 
the lack of consensus and evidence- bases concerning the 
treatment of underlying disorders in OAT patients.
Moreover, a tenth of the Norwegian OAT patients were 
dispensed a gabapentinoid in 2017, whereas nearly twice 
as many were dispensed this drug in Sweden. During 
the last decade, the dispensing of gabapentinoids has 
increased substantially in the general population in 
Norway and Sweden despite studies that point out that 
gabapentinoids are potentially addictive.7 24 31 32 46 System-
atic reviews evaluating the use of gabapentinoids indicate 
that patients with opioid addiction were at a particular risk 
of misusing pregabalin and gabapentin,7 46 and euphoria 
and sedative effects were described when combining with 
opioids. Therefore, it is worrying that dispensing rates of 
gabapentinoids were high and increasing among patients 
on OAT.
Overall, based on our data and existing knowledge, we 
are unable to sufficiently evaluate whether dispensing 
rates of potentially addictive drugs were disproportion-
ately high or even low among patients on OAT in Norway 
and Sweden during the study period. Some patients may 
have been undertreated considering their high burden 
of disease. On the other hand, a recent study has found 
that being dispensed gabapentinoids, z- hypnotics or 
benzodiazepines is associated with overdose death among 
patients on OAT.1 To stay on the safe side of this chal-
lenging matter, lower dispensing rates of these drugs may 
be preferable considering a high number of overdose 
deaths in Norway and Sweden during the last decade.30 47 
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indications, regular urine testing to prevent concomi-
tant street drug use, and close collaboration between 
prescribers of OAT opioids and those dispensing poten-
tially addictive drugs may be important measures to 
decrease future overdose deaths and ensure more reason-
able and safe treatment approaches among the highly 
morbid patients on OAT.
STRENGTHS AND LIMITATIONS
The use of national registry data has some advantages, 
as it can capture whole cohorts of the studied popula-
tions. The Norwegian Prescription Database and Swedish 
Prescribed Drug Register have advantages in that they 
receive all information concerning dispensed drugs from 
pharmacies in Norway and Sweden, except for those 
administered at hospitals, nursing homes and outpatient 
clinics. These registers are the most useful databases that 
identify reliable information regarding drug dispensing 
among patients on OAT.31 32
However, this study also has some limitations, mainly 
related to possible differences in selection bias between 
the studied populations. First, in both countries, patients 
may use methadone mixture for a medical indication 
other than OAT yet still be included in the OAT popu-
lation. To account for this, only patients who had been 
dispensed a mean dose of one or more DDD of meth-
adone mixture, levomethadone or buprenorphine/
buprenorphine- naloxone during a calendar year were 
included. Second, mean daily doses were calculated by 
summing all dispensed doses of the respective drugs 
during a calendar year divided by 365.25 days. Dividing 
the dispensed doses per year by 365.25 have some limita-
tions. Some patients may have been dispensed drugs in a 
higher mean daily dose within a shorter period than the 
calculations of mean daily doses per year indicate. Further, 
the drugs that were dispensed at the end of December 
for consumption in the following months were calculated 
as consumed in the year the drugs were dispensed. The 
latter could potentially signify that the mean daily doses 
were calculated higher than the dose recommended by 
the prescribers. Third, it is estimated that only about 60% 
of patients on OAT are identified through the Swedish 
Prescribed Drug Register; the remaining proportion may 
receive OAT opioids from specialised addiction outpa-
tient clinics within specialist healthcare.27 In Norway, it is 
estimated that 90% of patients who were dispensed OAT 
opioids were registered in the Norwegian Prescription 
Database.28 The fact that 40% of the Swedish patients 
were lacking could skew the results and affect the conclu-
sion. Patients who received OAT opioids from outpatient 
clinics may have more psychiatric and physical comor-
bidities and need more follow- ups than patients who 
were dispensed OAT opioids by pharmacies. Therefore, 
these comorbid patients who could not be captured by 
our study may have had higher dispensing rates of poten-
tially addictive drugs, meaning that the dispensing rates 
may have been underestimated in this study. Fourth, the 
Swedish Prescribed Drug Register does not provide data 
on patients who died during the study period. Due to this, 
patients were censored from the year with no dispensing 
Figure 1 The proportion of patients on OAT who were dispensed potentially addictive drugs in 2017. The figure displays 
the proportion of patients on OAT who were dispensed at least one potentially addictive drug, benzodiazepine, z- hypnotic, 
gabapentinoid, strong non- OAT opioid, weak non- OAT opioid and centrally acting stimulant in Norway and Sweden in 2017. 
Strong non- OAT opioids were defined as all opioid expect codeine, tramadol and tapentadol. Weak non- OAT opioids were 
defined as all drugs that contain codeine, tramadol or tapentadol. OAT, opioid agonist therapy.
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Table 3 Dispensed dose of potentially addictive drugs in the period from 2015 to 2017
Year 2015 2016 2017
Country Norway Sweden Norway Sweden Norway Sweden
Benzodiazepines
  Diazepam equivalents
   Number of patients 2622 438 2503 451 2556 421
   Mean (mg/year) 6920 6896 6585 6437 6216 5936
   Mean (mg/day/year) 19 19 18 18 17 16
   Median (mg/day/year) 10 10 10 9 10 9
   25 percentile (mg/day/year) 3 2 3 2 3 2
   75 percentile (mg/day/year) 21 22 21 21 20 21
Z- hypnotics
  Zopiclone equivalents
   Number of patients 912 750 834 760 798 721
   Mean (mg/year) 2867 3037 2904 2951 2942 3008
   Mean (mg/day/year) 8 8 8 8 8 8
   Median (mg/day/year) 5 7 6 6 6 7
   25 percentile (mg/day/year) 1 2 1 2 1 2
   75 percentile (mg/day/year) 10 12 10 12 11 12
Gabapentinoids
  Gabapentin
   Number of patients 192 164 183 203 207 213
   Mean (mg/year) 335 409 256 505 334 730 276 083 372 966 282 017
   Mean (mg/day/year) 918 702 916 755 1021 772
   Median (mg/day/year) 376 324 492 329 492 329
   25 percentile (mg/day/year) 82 82 82 82 164 82
   75 percentile (mg/day/year) 1287 992 1232 986 1203 986
  Pregabalin
   Number of patients 348 330 359 331 413 317
   Mean (mg/year) 134 777 123 510 144 551 119 335 146 684 126 122
   Mean (mg/day/year) 369 338 396 327 402 345
   Median (mg/day/year) 261 277 319 260 275 287
   25 percentile (mg/day/year) 66 138 92 117 82 149
   75 percentile (mg/day/year) 561 480 592 483 575 501
Centrally acting stimulants
  Methylphenidate
   Number of patients 143 400 151 392 143 346
   Mean (mg/year) 18 957 28 966 21 364 29 248 20 845 29 305
   Mean (mg/day/year) 52 79 58 80 57 80
   Median (mg/day/year) 48 69 52 71 57 70
   25 percentile (mg/day/year) 16 35 18 31 20 28
   75 percentile (mg/day/year) 75 109 85 112 85 114
  Lisdexamphetamine
   Number of patients 9 82 28 144 51 183
   Mean (mg/year) 4778 15 238 18 158 17 649 21 033 18 514
   Mean (mg/day/year) 13 42 50 48 58 51
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OAT opioids in both countries. The annual self- reported 
survey on the Norwegian OAT population indicated that 
the death rate is approximately 1.5% per 100 patient- 
year, which could constitute about 125 patients yearly in 
our Norwegian and Swedish population.28 Fifth, because 
no dispensed drugs in Sweden nor all non- reimbursed 
dispensations in Norway are necessarily linked to medical 
diagnostic codes, such as the International Statistical 
Classification of Diseases and Related Health Problems 
version 10, or the International Classification of Primary 
Care, the medical indications for the dispensations are 
not available to the researchers through the prescription 
register- based databases. Sixth, in 2016, Sweden changed 
the inclusion criteria to be granted OAT by including 
opioid- addicted patients with extensive opioid use caused 
by chronic severe pain.26 27 The proportion of patients 
receiving OAT opioids due to pain was not estimated in 
this study.
CONCLUSION
About half of patients who were dispensed an OAT opioid 
were codispensed potentially addictive drugs in Norway 
and Sweden. There were remarkable differences in the 
dispensing rates and dispensed doses of potentially addic-
tive drugs between OAT patients in these countries. This 
might be related to differences in national guidelines, 
a lack of evidence- based knowledge and international 
consensus on the treatment of comorbid conditions 
among patients on OAT or differences in the criteria 
required to be included and kept in OAT, which again 
may contribute to varying clinical practice and treatment 
approaches in OAT populations across the countries. We 
call for further research to investigate proper approaches 
for the treatment of comorbid conditions in patients 
undergoing OAT.
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